NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/19/2025
Back to search
Official data from USPTO
FIBROBODY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
FIBROBODY
ST13
US500000079321550Class
1, 5, 42, 44
Filing
79321550
Registration
6624524
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
09/20/2025
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
02/18/2021
Registration date
01/25/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/25/2022
Last transaction
09/20/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
16
Owner location
NL
Examiner
ROACH, APRIL
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
LinXis B.V.
Representatives
KILBURN & STRODE LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals for treating fibrotic diseaseliver- kidney- and lung fibrosisinflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease
Class 5
Pharmaceutical preparations for the treatment of fibrotic diseaseliver- kidney- and lung fibrosisinflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and per-oral formulationstablets and capsules that facilitate the delivery of pharmaceutical preparations; pharmaceutical drugs for the treatment of fibrotic diseaseliver- kidney- and lung fibrosisinflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents in the form of parenteral formulations and per-oral formulationstablets and capsules that facilitate the delivery of pharmaceutical preparations; biochemical medicines for the treatment of fibrotic diseaseliver- kidney- and lung fibrosisinflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; chemical preparations for pharmaceutical purposesfor the treatment of fibrotic diseaseliver- kidney- and lung fibrosisinflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; diagnostic agents for pharmaceutical purposes; pharmaceutical substances and preparations for the treatment of fibrotic diseaseliver- kidney- and lung fibrosisinflammatory conditions with a proven fibrotic disease component and inflammatory bowel disease; drug delivery agents consisting of compounds that facilitate delivery of pharmaceutical preparations
Class 42
Pharmaceutical research services; conducting clinical trials for others relating to pharmaceuticals; pharmaceutical research and development; pharmaceutical product evaluation; consultancy relating to pharmaceutical research and development; laboratory research services relating to pharmaceuticals; providing information about the results of clinical trials for pharmaceuticals; providing information about medical and scientific research in the field of pharmaceuticals; scientific research services in the field of proteinsantibodiesmicroorganisms and cells; research and development services in the field of antibody technology; design and development of medical technology
Class 44
Medical servicesin vitro analysis for medical and pharmaceutical use; medical servicesin vitro testing for medical and pharmaceutical use; consultancy and information services provided via the internet relating to pharmaceutical products
Publications
History of USPTO decisions and trademark events.
16 publications found
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
03/14/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/20/2024
GPNX
NOTIFICATION PROCESSED BY IB
06/05/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/19/2022
FIMP
FINAL DISPOSITION PROCESSED
05/18/2022
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
02/24/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/25/2022
PUBO
PUBLISHED FOR OPPOSITION
11/09/2021
NPUB
NOTICE OF PUBLICATION
10/20/2021
MAFR
APPLICATION FILING RECEIPT MAILED
10/12/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/06/2021
DOCK
ASSIGNED TO EXAMINER
10/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/06/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
10/04/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/30/2021
Continuous trademark protection
Get notified about every new filing that threatens FIBROBODY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.